Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-MCBS Scorecards

ESMO MCBS  1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 95
3 125
2 34
1 19
Curative setting
A 38
C 2
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 28
Central Nervous System Malignancies 0
Endocrine Tumours 19
Gastrointestinal Cancers 53
Genitourinary Cancers 51
Gynaecological Malignancies 30
Head and neck cancer 6
Refractory NTRK fusion–positive cancers 2
Sarcoma 10
Skin Cancers 24
TMB-H solid tumours 1
Thoracic Malignancies 65
dMMR/MSI-H solid tumours 1
Curative setting
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 4
Gynaecological Malignancies 0
Head and neck cancer 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 8
TMB-H solid tumours 0
Thoracic Malignancies 2
dMMR/MSI-H solid tumours 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Evaluation form 1 For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Lenvatinib Pembrolizumab Sunitinib First-line treatment Genitourinary Cancers Renal cell cancer - CLEAR
    4

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Enfortumab vedotin - Investigator-chosen ChT (standard docetaxel, paclitaxel or vinflunine) Treatment of adult patients who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor Genitourinary Cancers Urothelial Carcinoma - EV-301
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Nivolumab Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX) ChT (FOLFOX or CAPOX) First‑line treatment of adult patients with HER2‑negative whose tumours express PD-L1 with a CPS ≥5 Gastrointestinal Cancers Gastric or gastro-oesophageal junction cancer and oseophageal adenocarcinoma HER2- PD-L1 CPS ≥5 CHECKMATE-649
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Pembrolizumab - ChT ((5-fluorouracil–based therapy with or without bevacizumab or cetuximab) First‑line treatment of metastatic microsatellite instability‑high (MSI‑H) or mismatch repair deficient (dMMR) colorectal cancer in adults. Gastrointestinal Cancers Colorectal Cancer dMMR or MSI-H KEYNOTE-177
    4

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Pembrolizumab ChT with our without bevacizumab Placebo + ChT with our without bevacizumab First-line treatment Gynaecological Malignancies Cervical Cancer PD-L1 (CPS ≥1) KEYNOTE-826
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Pembrolizumab Cisplatin and 5-FU ChT Placebo + cisplatin and 5-FU ChT First-line treatment Gastrointestinal Cancers Oesophageal or gastroesophageal carcinoma HER2- GEJ PD-L1 CPS ≥10 KEYNOTE-590
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Pembrolizumab Cisplatin and 5-FU ChT Placebo + cisplatin and 5-FU ChT First-line treatment Gastrointestinal Cancers Oesophageal or gastroesophageal carcinoma HER2- GEJ PD-L1 (squamous cell) CPS ≥10 KEYNOTE-590
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Tebentafusp - Investigator Choice (either dacarbazine, ipilimumab or pembrolizumab) Treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma Skin Cancers Uveal melanoma HLA-A*0201positive IMCgp100-202
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Relugolix - Leuprolide Therapy with either prostate cancer recurrence following radiation or surgery or newly diagnosed castration-sensitive advanced prostate cancer Genitourinary Cancers Prostate cancer - HERO
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Nivo/Ipi (nivolumab and ipilimumab) - ChT First-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1% Gastrointestinal Cancers Oesophageal Cancer PD-L1 expression ≥1% CheckMate 648
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.